Paediatric oral formulations: Why don't our kids have the medicines they need?-Reference-Cited by-同舟云学术

Paediatric oral formulations: Why don't our kids have the medicines they need?

Published:2022-07-23 Issue:10 Volume:88 Page:4337-4348
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Juárez‐Hernández José Eduardo¹²,Carleton Bruce C.¹²³^ORCID

Affiliation:

1. Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine University of British Columbia Vancouver Canada

2. BC Children's Hospital Research Institute Vancouver Canada

3. Pharmaceutical Outcomes Programme BC Children's Hospital Vancouver Canada

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15456

Reference68 articles.

1. United Nations Department of Economic and Social Affairs.World Population Prospects 2019.2019.

2. KnutsenA ButlerAS VanchieriC.Addressing the Barriers to Pediatric Drug Development: Workshop Summary.2008: Institute of Medicine of the national academies.

3. United States Food and Drug Administration.Drug Research and Children.2016[cited 2020 January 29]. Available from:https://www.fda.gov/drugs/drug-information-consumers/drug-research-and-children

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commercialization of the Xalkori Pediatric Multiparticulate Product Using Quality-by-Design Principles;Pharmaceutics;2024-08-01

2. Younger Children with Respiratory Tract Infections Are More Exposed to Off-Label Treatments: An Exploratory Retrospective Study in a Pediatric Emergency Setting;Children;2024-06-16

3. Leading Paediatric Infectious Diseases—Current Trends, Gaps, and Future Prospects in Oral Pharmacotherapeutic Interventions;Pharmaceutics;2024-05-26

4. Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines;BMJ Public Health;2024-02

5. Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania;PLOS ONE;2024-01-02